(Agreements as at September 15, 2003)
|
We acknowledge contribution for special sponsored Symposia and Congress Organization by |
||||||||||||
| Ares Serono | The management of the infertile couple: ovulation induction | |||||||||||
| Effik | Micronized progesterone: the natural molecule for HRT | |||||||||||
| Guidotti | Hyperinsulinemia, hyperandrogenism and polycystic ovary syndrome: the new challenge of Metformin | |||||||||||
| IBSA | From ovarian induction to pregnancy maintenance | |||||||||||
| Named | New scientific insight in efficacy and safety for women | |||||||||||
| Organon | Mammographic density and its implication for individual human | |||||||||||
| Procter & Gamble | Female sexual function and androgen treatment | |||||||||||
| Schering | Drospirenone: more than a progestin | |||||||||||
| Solvay Pharmaceuticals | Satellite Symposium | |||||||||||
| Theramex/Merck | What could be the impact of the regimen and type of progestin on successful hormone replacement therapy in the future? | |||||||||||
| Lilly/ Menarini | Title to be defined | |||||||||||
| Rottapharm | Title to be defined | |||||||||||
| Wyeth | Title to be defined | |||||||||||
|
We acknowledge contribution
for special Lectures
and Congress Organization by |
||||||||||||
|
||||||||||||
|
We also acknowledge contribution
for Congress organization by |
||||||||||||
|
||||||||||||